38、卫材(Eisai) 日本 45.96亿美元/12.28亿美元 39、中国生物制药(Sino Biopharmaceutical) 中国香港 44.63亿美元/6.01亿美元 40、费森尤斯卡比(Fresenius) 德国 43.42亿美元/9.25亿美元 41、上海医药集团(Shanghai Pharmaceuticals Holding)中国 40.43亿美元/2.61亿美元 ...
42、中国生物制药(Sino Biopharmaceutical) 中国香港 33.73亿美元/3.47亿美元 43、江苏恒瑞医药(Jiangsu Hengrui Medicine) 中国 33.21亿美元/5.18亿美元 44、小野(Ono Pharmaceutical) 日本 32.66亿美元/6.53亿美元 45、美纳里尼(Menarini) 意大利 32.33亿美元/-- 46、远藤国际(Endo International) 爱尔兰 28.87亿美元...
But for the biopharmaceutical industry in recent decades, where the pace of change was notoriously slow-going—at least according to outside perception—it’s safe to say the last few calendar turns, impacted, of course, by a global health pandemic, have proven that things are no longer ...
美国《制药经理人》杂志发布了“2024年度全球制药企业50强排行榜”。榜单依据各大药企2023年处方药销售收入进行排序,其中强生公司以534.63亿美元的处方药销售收入位居榜首,艾伯维、诺华分列榜单第2、3名,中国有云南白药(33名)、中国生物制药(38名)、上海医药(42名)以及恒瑞医药(48名)4家企业上榜。下面小编已经把榜...
[1] Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData. Retrieved February 21, 2024 from https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-report-1-6-market-capitalization-growth-...
2.https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-report-1-6-market-capitalization-growth-to-3-67-trillion-in-2023-reveals-globaldata/ FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」...
[1] Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData. Retrieved February 21, 2024 from网页链接 [2] Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023. Retrieved February 21, 2024 from网页链接 ...
[1] Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData. Retrieved February 21, 2024 from https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharm...
Not surprisingly, in a survey recognizing how enterprises such as the biopharmaceutical indus- of pharma C-suite executives conducted by Model N, 58% said try performed and responded during the Year of COVID—in that the pandemic had the biggest impact on the way their com- bottom-line ...
Biopharma Companies to KnowGRAIL View Profile We are hiring GRAIL is a healthcare company focused on early cancer detection. Its biopharmaceutical innovations in multi-cancer early detection, novel cancer therapeutics, liquid biopsy solutions and methylation have pushed the industry forward, making cancer...